Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TRC20-USDT Issuance Surpasses 77.7 Billion, Setting a New Record

TRC20-USDT Issuance Surpasses 77.7 Billion, Setting a New Record

星球日报星球日报2025/05/21 13:27
Show original

The issuance of TRC20-USDT has increased to 77.7 billion, setting a new historical high. Since the beginning of this year, the TRON network has issued nearly 18 billion additional USDT. As of now, TRC20-USDT accounts for more than half of the total USDT issuance across the network, with 66.25 million holding accounts and over 2.52 billion cumulative transfers. TRON founder Justin Sun previously stated at TOKEN2049 Dubai that TRON's goal is for the total market value of stablecoins to exceed $100 billion this year.

TRC20-USDT is a dollar-pegged stablecoin issued by Tether on the TRON network, characterized by fast transfer speeds and low transaction fees, which have attracted a large number of users and support from multiple exchanges. The TRC20 version of USDT will significantly enhance TRON's existing decentralized application ecosystem, bringing higher overall value storage and stronger decentralized exchange liquidity, and providing a more convenient blockchain entry for enterprise partners and institutional investors.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.

智通财经•2026/10/26 06:41
"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential

Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.

智通财经•2026/10/26 06:37